CD34 and FSHR Expression to Differentiate Multiple Subtypes of Benign and Malignant Renal Neoplasms

CD34 and FSHR Expression to Differentiate Multiple Subtypes of Benign and Malignant Renal Neoplasms

BackgroundCurrently, no markers accurately differentiate benign from malignant renal masses. CD34 and FSHR are transmembrane proteins involved in neo-angiogenetic pathways and are differently expressed in several normal and cancerous tissues. However, little evidence exists on their distribution in...

Full description

Bibliographic Details
Main Authors: Giancarlo Marra, Didier Meseure, Marine Lefèvre, Andre Nicolas, Laetitia Lesage, Nicolae Ghinea, Marco Moschini, Caio Pasquali, Petr Macek, Claudia Filippini, Paolo Gontero, Rafael Sanchez-Salas, Xavier Cathelineau
Format: Article
Language:English
Published: The Société Internationale d’Urologie (SIU) 2022-05-01
Series:Société Internationale d’Urologie Journal
Subjects:
kidney cancer
cd34
fshr
tumor markers
Online Access:https://siuj.org/index.php/siuj/article/view/183/115

Internet

https://siuj.org/index.php/siuj/article/view/183/115

Similar Items